跳至主要内容
临床试验/EUCTR2007-002911-18-SE
EUCTR2007-002911-18-SE进行中(未招募)不适用

Comparison of the T4/T1 ratio measured by means of the TOF-Watch® SX with the reappearance of T4 measured by means of a peripheral nerve stimulator in adult subjects receiving 4.0 mg.kg-1 sugammadex at 15 minutes after rocuronium

V Organon0 个研究点目标入组 90 人开始时间: 2007年7月19日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
90

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Male or female subjects:
  • of ASA Class 1 or 2 or 3;
  • between the ages of 18 to 64 years, inclusive;
  • scheduled for a surgical procedure under general anesthesia requiring neuromuscular relaxation
  • with the use of rocuronium;
  • scheduled for a surgical procedures in supine position;
  • who have given written informed consent.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Subjects in whom a difficult intubation because of anatomical malformations is expected;
  • Subjects known or suspected to have neuromuscular disorders impairing neuromuscular blockade
  • and/or significant hepatic and/or renal dysfunction;
  • Subjects with a medical or physical condition that is expected to interfere with the proper conduct of
  • simultaneous neuromuscular monitoring on both arms;
  • Subjects known or suspected to have a (family) history of malignant hyperthermia;
  • Subjects known or suspected to have arthritis or another disease that will cause the thumb not to
  • move freely;
  • Subjects known or suspected to have an allergy to narcotics, muscle relaxants or other medication
  • used during general anesthesia;
  • Subjects receiving medication in a dose and/or at a time point known to interfere with NMBAs,
  • such as antibiotics, anticonvulsants and Mg2+;
  • Subjects who have already participated in a sugammadex trial;
  • Subjects who have participated in another clinical trial, not pre-approved by NV Organon,
  • within 30 days of entering into CT 19.4.313;
  • Female subjects who are pregnant*;
  • Female subjects who are breast-feeding.
  • * In female subjects pregnancy will be excluded both from medical history and by an hCG test within 24 hours before surgery except in females who are not of childbearing potential, i.e. at least 2 years menopausal or have undergone tubal ligation or an hysterectomy.

研究者

发起方
V Organon

相似试验

Comparison of the T4/T1 ratio measured by means of... | 临床试验